Read by QxMD icon Read

pitavastAtin risk cardiovascular

Yusuke Miyazaki, Yasufumi Katanasaka, Yoichi Sunagawa, Sae Hirano-Sunagawa, Masafumi Funamoto, Eriko Morimoto, Maki Komiyama, Akira Shimatsu, Noriko Satoh-Asahara, Hajime Yamakage, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto
PURPOSE: HMG-CoA reductase inhibitors, also termed statins, are used to reduce the risk of coronary artery disease. Two oxidatively modified low-density lipoprotein (LDL) complexes, serum amyloid A-LDL (SAA-LDL) and α1-antitrypsin-LDL (AT-LDL), serve as atherosclerotic, inflammatory, and cardiovascular risk markers. In this study, we examined the effects of hydrophilic rosuvastatin (RSV) and lipophilic pitavastatin (PTV) on these markers in patients with hypercholesterolemia. METHODS: The present study was a sub-analysis of our previous STAT-LVDF study...
October 3, 2016: International Journal of Cardiology
Asita Wongprikorn, Chonlaphat Sukasem, Apichaya Puangpetch, Pawin Numthavej, Ammarin Thakkinstian, Sasisopin Kiertiburanakul
BACKGROUND: Dyslipidemia as a risk factor of cardiovascular disease is common especially in HIV-infected patients who are using protease inhibitors (PIs) including atazanavir. Pitavastatin has less drug-drug interactions and demonstrable efficacy in decreasing lipid levels in non HIV-infected individuals. MATERIALS AND METHODS: This study was a randomized, double-blind, crossover study comparing the safety and efficacy of pitavastatin vs placebo in HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir (ATV/r)...
2016: PloS One
Rioto Suzuki, Yutaka Nakamura, Shinji Chiba, Tomoki Mizuno, Kazuyuki Abe, Yosuke Horii, Hiromi Nagashima, Tatsuo Tanita, Kohei Yamauchi
BACKGROUND: Statin use in individuals with chronic obstructive pulmonary disease (COPD) with coexisting cardiovascular disease is associated with a reduced risk of exacerbations. The mechanisms by which statin plays a role in the pathophysiology of COPD have not been defined. To explore the mechanisms involved, we investigated the effect of statin on endothelial cell function, especially endothelial cell tight junctions. METHOD: We primarily assessed whether pitavastatin could help mitigate the development of emphysema induced by continuous cigarette smoking (CS) exposure...
May 11, 2016: Pulmonary Pharmacology & Therapeutics
Vivencio Barrios, Carlos Escobar
Despite attaining LDL-cholesterol targets, many patients with diabetes remain at risk of developing cardiovascular events. In addition, treatment with statins has been associated with a slight but significant increased risk of development of diabetes, particularly with high-intensity statins. Pitavastatin is a moderate- to high-intensity statin that effectively reduces LDL-cholesterol levels. Pitavastatin provides a sustained increase of HDL-cholesterol levels that may exhibit a neutral or positive effect on glucose metabolism, may not increase the risk of new-onset diabetes, may exhibit positive effects on renal function and urinary albumin excretion and the risk of drug-drug interactions is low...
July 2016: Future Cardiology
Hyo Sun Lee, Chang Hee Jung, Sung Rae Kim, Hak Chul Jang, Cheol Young Park
BACKGROUND: Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA₂ levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study...
March 2016: Endocrinology and Metabolism
Jennifer M Gilbert, Kathleen V Fitch, Steven K Grinspoon
HIV infection is associated with increased cardiovascular disease (CVD), and increased rates of myocardial infarction and stroke have been observed in HIV-infected individuals. After traditional risk factors that are more common among people living with HIV infection (such as smoking and diabetes) are accounted for, the excess risk for CVD persists. Recent studies suggest that increased immune activation and inflammation may contribute to excess risk for CVD in the context of HIV infection. Imaging studies in the HIV-infected population have found inflamed, noncalcified plaque that is vulnerable to rupture...
October 2015: Topics in Antiviral Medicine
Chris T Longenecker, Allison R Eckard, Grace A McComsey
PURPOSE OF REVIEW: To evaluate evidence that statins reduce cardiovascular risk in patients living with HIV. RECENT FINDINGS: Moderate to high-dose atorvastatin and rosuvastatin appear to reduce noncalcified coronary plaque volume and slow progression of carotid intima-media thickness in patients with treated HIV infection. Expected lipoprotein changes with statins on the background of modern antiretroviral therapy are similar to the general population. In addition to lipids, the statin benefit may be mediated in part by improvements in vascular inflammation and levels of T-cell and monocyte activation...
February 2016: Current Opinion in Infectious Diseases
Masato Ohsawa, Kouichi Tamura, Hiromichi Wakui, Tomohiko Kanaoka, Kengo Azushima, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Yoshiyuki Toya, Satoshi Umemura
BACKGROUND: In non-dialysis chronic kidney disease (CKD) patients with dyslipidemia, statin therapy is recommended to prevent cardiovascular complications. Dyslipidemia has been also shown to be an independent risk factor for the progression of CKD. However, it is still unclear whether statin therapy exerts an inhibitory effect on renal deterioration in CKD patients with dyslipidemia. The purpose of the present study was to examine possible therapeutic effects of statin add-on therapy on renal function as well as parameters of lipid and glucose metabolism, arterial stiffness and oxidative stress, in comparison to diet therapy, in CKD patients with dyslipidemia...
2015: Lipids in Health and Disease
Tom J J Schirris, Tina Ritschel, Albert Bilos, Jan A M Smeitink, Frans G M Russel
Statins are cholesterol-lowering drugs that have proven to be effective in lowering the risk of major cardiovascular events. Although well tolerated, statin-induced myopathies are the most common side effects. Compared to their pharmacologically active acid form, statin lactones are more potent inducers of toxicity. They can be formed by glucuronidation mediated by uridine 5'-diphospho-glucuronosyltransferases (UGTs), but a systematic characterization of subtype specificity and kinetics of lactonization is lacking...
November 2, 2015: Molecular Pharmaceutics
Francesco Pelliccia, Fabiana Rollini, Giuseppe Marazzi, Cesare Greco, Carlo Gaudio, Dominick J Angiolillo
The combination of aspirin and the thienopyridine clopidogrel is a cornerstone in the prevention of atherothrombotic events. These two agents act in concert to ameliorate the prothrombotic processes stimulated by plaque rupture and vessel injury complicating cardiovascular disease. Guidelines recommend the use of clopidogrel in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention, and the drug remains the most utilized P2Y12 receptor inhibitor despite the fact that newer antiplatelet agents are now available...
October 15, 2015: European Journal of Pharmacology
Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis
Chronic kidney disease (CKD) is highly prevalent worldwide and represents a major cardiovascular risk factor. Dyslipidemia is present in most patients with CKD and further worsens CKD, creating a vicious cycle. The treatment of CKD-related dyslipidemia has been a controversial topic. The use of statins is recommended in all stages of CKD, but it appears to reduce cardiovascular and renal events only in the early CKD stages, up to stage 3. The use of atorvastatin has proven very beneficial; thus, the earliest we start statin treatment, the better for the patient...
2015: Expert Review of Cardiovascular Therapy
Masahiko Gosho, Masaya Tanahashi, Neil Hounslow, Tamio Teramoto
OBJECTIVES: Medications that interact with the pathways responsible for statin metabolism may increase the risk of statin-associated myalgia. Pharmacokinetic studies show that pitavastatin is carried into the liver by a range of transporters and is minimally metabolized by cytochrome P450 in healthy volunteers, indicating a reduced potential for drug-drug interactions (DDIs). This post hoc analysis investigates the incidence of adverse events in patients receiving pitavastatin with concomitant medication in two large data sets...
August 2015: International Journal of Clinical Pharmacology and Therapeutics
Marjet J A M Braamskamp, Claudia Stefanutti, Gisle Langslet, Euridiki Drogari, Albert Wiegman, Neil Hounslow, John J P Kastelein
OBJECTIVES: To assess the safety and efficacy of pitavastatin in children and adolescents with hyperlipidemia. STUDY DESIGN: A total of 106 children and adolescents with hyperlipidemia, ages 6 to 17 years, were enrolled in a 12-week randomized, double-blind, placebo-controlled study and randomly assigned to pitavastatin 1 mg, 2 mg, 4 mg, or placebo. During a 52-week extension period, subjects were up-titrated from 1 mg pitavastatin to a maximum dose of 4 mg in an effort to achieve an optimum low-density lipoprotein cholesterol (LDL-C) treatment target of <110 mg/dL (2...
August 2015: Journal of Pediatrics
Matthew J Feinstein, Chad J Achenbach, Neil J Stone, Donald M Lloyd-Jones
HIV-infected patients have a greater prevalence of dyslipidemia, earlier incidence and progression of atherosclerosis, and a nearly twofold increased risk for myocardial infarction compared with those not infected with HIV. Pre-existing cardiovascular risk factors, viral replication, and antiviral treatments all contribute to this accelerated and increased risk for cardiovascular disease in HIV-infected subjects. Given this risk and the proven benefit of statins reducing cardiovascular events across numerous patient groups, statin therapy might be particularly beneficial for patients with HIV...
June 15, 2015: American Journal of Cardiology
Joan Rius Tarruella, Jesús Millán Núñez-Cortés, Juan Pedro-Botet, Xavier Pintó Sala
Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus (T2DM). However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients with or without DM2, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity. In many statin trials the incidence of DM2 has not been systematically evaluated and others the power to detect differences between statins is lacking...
May 2015: Clínica e Investigación en Arteriosclerosis
Masanobu Ishii, Seiji Hokimoto, Tomonori Akasaka, Kazuteru Fujimoto, Yuji Miyao, Koichi Kaikita, Shuichi Oshima, Koichi Nakao, Hideki Shimomura, Ryusuke Tsunoda, Toyoki Hirose, Ichiro Kajiwara, Toshiyuki Matsumura, Natsuki Nakamura, Nobuyasu Yamamoto, Shunichi Koide, Hideki Oka, Yasuhiro Morikami, Naritsugu Sakaino, Kunihiko Matsui, Hisao Ogawa
BACKGROUND: The aim of this study was to examine the effects of different statins on the clinical outcomes of Japanese patients with coronary stent implants. METHODS AND RESULTS: This study included 5,801 consecutive patients (males, 4,160; age, 69.7±11.1 years, mean±SD) who underwent stent implantation between April 2008 and March 2011. They were treated with a strong statin (n=3,042, 52%, atorvastatin, pitavastatin, or rosuvastatin), a regular statin (n=1,082, 19%, pravastatin, simvastatin, or fluvastatin) or no statin (n=1,677, 29%)...
2015: Circulation Journal: Official Journal of the Japanese Circulation Society
Juan Cosin Sales, Francisco José Fuentes Jiménez, Teresa Mantilla Morató, Emilio Ruiz, Virginia Becerra, Susana Aceituno, Maria Giovanna Ferrario, Luis Lizán, Alfredo Gracia
INTRODUCTION AND OBJECTIVES: To estimate the cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in Spain, according to the European guidelines for the treatment of dyslipidemias in patients with high and very high cardiovascular risk. METHODS: A Markov long-term cost-effectiveness model of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk defined according to 5 factors (sex, age, smoking habit, baseline cholesterol level, and systolic blood pressure) using the SCORE system...
September 2015: Clínica e Investigación en Arteriosclerosis
Lorenzo Arnaboldi, Alberto Corsini
Statins represent the elective lipid-lowering strategy in hyperlipidemic and high cardiovascular-risk patients. Despite excellent safety and tolerability, reversible muscle-related and dose-dependent adverse events may decrease a patient's compliance. Large meta-analyses, post-hoc and genetic studies showed that statins might increase the risk of new-onset diabetes (NOD), particularly in insulin-resistant, obese, old patients. Race, gender, concomitant medication, dose and treatment duration may also contribute to this effect...
January 2015: Atherosclerosis. Supplements
Yongin Cho, EunYeong Choe, Yong-Ho Lee, Ji Won Seo, Younjeong Choi, Yujung Yun, Hye Jin Wang, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
OBJECTIVE: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are used to control blood cholesterol levels and reduce cardiovascular disease. It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM). However, limited evidence exists from direct head to head comparisons of statins on whether the risk of DM differs among statins. We investigated the risk of development of new-onset diabetes in subjects treated with different statins. METHODS: We retrospectively enrolled consecutive 3680 patients without DM or impaired fasting glucose who started receiving statin treatment for cholesterol control...
April 2015: Metabolism: Clinical and Experimental
Sung Hee Choi, Soo Lim, Eun Shil Hong, Ji A Seo, Cheol-Young Park, Jung Hyun Noh, Ji Oh Mok, Ki Young Lee, Jong Sook Park, Dae Jung Kim, Chang Beom Lee, Sung Rae Kim, Hak Chul Jang
OBJECTIVE: Dyslipidaemia and central obesity are the major factors underlying the dramatic increase in metabolic syndrome (MS). We compared the effects of early combined therapy with pitavastatin and intensive lifestyle modification (LSM) on the amelioration of each component of MS with those of LSM only. DESIGN/PARTICIPANTS/MEASUREMENTS: PROPIT (a PROspective comparative clinical study to evaluate the efficacy and safety of PITavastatin in patients with metabolic syndrome) was a prospective, randomized, multicenter open-label 48-week trial...
May 2015: Clinical Endocrinology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"